^
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CTX110 Sensitive: B - Late Trials
CRISPR Therap Press Release - 1 week
|
CTX110 Sensitive: B - Late Trials
CRISPR Therap Press Release - 1 week
|
IDH2 mutation
|
ALL
|
IDH2 mutation
|
ALL
|
enasidenib Sensitive: B - Late Trials
ASH 2021 - 3 weeks
|
enasidenib Sensitive: B - Late Trials
ASH 2021 - 3 weeks
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
PBCAR0191 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
PBCAR0191 Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
CD22 overexpression
|
ALL
|
CD22 overexpression
|
ALL
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
CD22 underexpression+BCL2 overexpression
|
ALL
|
CD22 underexpression+BCL2 overexpression
|
ALL
|
inotuzumab ozogamicin Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
|
inotuzumab ozogamicin Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
|
KMT2A rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
KMT2A rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
blinatumomab Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
BCR-ABL1 T315I
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 T315I
|
B Acute Lymphoblastic Leukemia
|
VPD Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
VPD Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
|
TP53 mutation
|
T Acute Lymphoblastic Leukemia
|
TP53 mutation
|
T Acute Lymphoblastic Leukemia
|
CD7-targeted CAR-T immunotherapy Sensitive: C4 – Case Studies
ASH 2021 - 3 weeks
|
CD7-targeted CAR-T immunotherapy Sensitive: C4 – Case Studies
ASH 2021 - 3 weeks
|
PAX5-JAK2 fusion
|
ALL
|
PAX5-JAK2 fusion
|
ALL
|
CHZ868 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
CHZ868 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
IL7R expression
|
B Acute Lymphoblastic Leukemia
|
IL7R expression
|
B Acute Lymphoblastic Leukemia
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
KMT2A rearrangement
|
ALL
|
KMT2A rearrangement
|
ALL
|
FLT3 inhibitor + gilteritinib Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
FLT3 inhibitor + gilteritinib Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
TCF3-PBX1 fusion
|
B Acute Lymphoblastic Leukemia
|
TCF3-PBX1 fusion
|
B Acute Lymphoblastic Leukemia
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
OSE-127 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
venetoclax Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
venetoclax Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
KRAS mutation
|
ALL
|
KRAS mutation
|
ALL
|
venetoclax Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
venetoclax Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
CD74 expression
|
ALL
|
CD74 expression
|
ALL
|
STRO-001 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
STRO-001 Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
ASH 2021 - 3 weeks
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
PD-L1 inhibitor + nilotinib Sensitive: D – Preclinical
SITC 2021 - 3 weeks
|
PD-L1 inhibitor + nilotinib Sensitive: D – Preclinical
SITC 2021 - 3 weeks
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
dasatinib + SBI-756 Sensitive: D – Preclinical
Sci Rep - 3 weeks
|
dasatinib + SBI-756 Sensitive: D – Preclinical
Sci Rep - 3 weeks
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
CD22 positive
|
B Acute Lymphoblastic Leukemia
|
CD22 positive
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
nelarabine Sensitive: A1 - Approval
|
nelarabine Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
dasatinib Sensitive: A1 - Approval
|
dasatinib Sensitive: A1 - Approval
|
CD19 positive
|
ALL
|
CD19 positive
|
ALL
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
mercaptopurine Sensitive: A1 - Approval
|
mercaptopurine Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
vincristine liposomal Sensitive: A1 - Approval
|
vincristine liposomal Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
|
blinatumomab Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
inotuzumab ozogamicin Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
pegaspargase Sensitive: A1 - Approval
|
pegaspargase Sensitive: A1 - Approval
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317I
|
ALL
|
BCR-ABL1 F317I
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 T315I
|
ALL
|
BCR-ABL1 T315I
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
PDGFRA fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
PDGFRA fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
ABL2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ABL2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
FGFR fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
FGFR fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
IL7R mutation
|
Childhood B Acute Lymphoblastic Leukemia
|
IL7R mutation
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
SH2B3 alteration
|
Childhood B Acute Lymphoblastic Leukemia
|
SH2B3 alteration
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
CRLF2 rearrangement + JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
CRLF2 rearrangement + JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
EPOR rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
EPOR rearrangement
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
bosutinib Sensitive: A2 - Guideline
|
bosutinib Sensitive: A2 - Guideline
|
BCR-ABL1 E255V
|
ALL
|
BCR-ABL1 E255V
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
CALGB 10403 Sensitive: A2 - Guideline
|
CALGB 10403 Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
ABL1 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ABL1 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
JAK2 fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
prednisone + vincristine Sensitive: A2 - Guideline
|
prednisone + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline
|
ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
cytarabine + methotrexate Sensitive: A2 - Guideline
|
cytarabine + methotrexate Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
cyclophosphamide oral + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
cyclophosphamide oral + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
clofarabine Sensitive: A2 - Guideline
|
clofarabine Sensitive: A2 - Guideline
|
PDGFRB fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
PDGFRB fusion
|
Childhood B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A2 - Guideline
|
tisagenlecleucel-T Sensitive: A2 - Guideline
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
cyclophosphamide oral + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
cyclophosphamide oral + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
cytarabine + cyclophosphamide oral + vincristine + methotrexate + pegaspargase Sensitive: A2 - Guideline
|
cytarabine + cyclophosphamide oral + vincristine + methotrexate + pegaspargase Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline
|
vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
cyclophosphamide oral + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
cyclophosphamide oral + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
imatinib Sensitive: A2 - Guideline
|
imatinib Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
cyclophosphamide oral + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
cyclophosphamide oral + etoposide oral + clofarabine Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
bortezomib Sensitive: A2 - Guideline
|
bortezomib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A2 - Guideline
|
blinatumomab Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
BCR-ABL1 G250E
|
ALL
|
BCR-ABL1 G250E
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 fusion
|
ALL
|
BCR-ABL1 fusion
|
ALL
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
inotuzumab ozogamicin Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline
|
blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline
|
ABL1 T315I
|
ALL
|
ABL1 T315I
|
ALL
|
ponatinib Sensitive: A2 - Guideline
|
ponatinib Sensitive: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 V299L
|
ALL
|
BCR-ABL1 V299L
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 F359I
|
ALL
|
BCR-ABL1 F359I
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F359C
|
ALL
|
BCR-ABL1 F359C
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F359V
|
ALL
|
BCR-ABL1 F359V
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 E255K
|
ALL
|
BCR-ABL1 E255K
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 Y253H
|
ALL
|
BCR-ABL1 Y253H
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F317C
|
ALL
|
BCR-ABL1 F317C
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317V
|
ALL
|
BCR-ABL1 F317V
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 T315A
|
ALL
|
BCR-ABL1 T315A
|
ALL
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
ALL
|
BCR-ABL1 F317L
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 G250E
|
ALL
|
BCR-ABL1 G250E
|
ALL
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
CD20 positive
|
ALL
|
CD20 positive
|
ALL
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
COG AALL0232 Sensitive: A2 - Guideline
|
COG AALL0232 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
MRC UKALLXII/ECOG2993 Sensitive: A2 - Guideline
|
MRC UKALLXII/ECOG2993 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
Linker 4-drug Sensitive: A2 - Guideline
|
Linker 4-drug Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
CALGB 8811 Larson Sensitive: A2 - Guideline
|
CALGB 8811 Larson Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
USC/MSKCC ALL Sensitive: A2 - Guideline
|
USC/MSKCC ALL Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
PETHEMA ALL-96 Sensitive: A2 - Guideline
|
PETHEMA ALL-96 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
GRAALL-2005 Sensitive: A2 - Guideline
|
GRAALL-2005 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
DFCI ALL Sensitive: A2 - Guideline
|
DFCI ALL Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
COG AALL0434 Sensitive: A2 - Guideline
|
COG AALL0434 Sensitive: A2 - Guideline
|
No biomarker
|
ALL
|
No biomarker
|
ALL
|
prednisone + vincristine + daunorubicin + pegaspargase Sensitive: A2 - Guideline
|
prednisone + vincristine + daunorubicin + pegaspargase Sensitive: A2 - Guideline
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
prednisone + vincristine + daunorubicin + nelarabine + pegaspargase Sensitive: A2 - Guideline
|
prednisone + vincristine + daunorubicin + nelarabine + pegaspargase Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
bosutinib Sensitive: A2 - Guideline
|
bosutinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
ponatinib Sensitive: A2 - Guideline
|
ponatinib Sensitive: A2 - Guideline
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
vincristine liposomal Sensitive: A2 - Guideline
|
vincristine liposomal Sensitive: A2 - Guideline
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
FLAG-IDA Sensitive: A2 - Guideline
|
FLAG-IDA Sensitive: A2 - Guideline
|
